Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function

British Journal of Haematology

Volumn 175, Issue 4, 2016, Pages 714-723

  Shi, Patricia A ^a   Choi, Erika ^a   Chintagari, Narendranath R ^b   Nguyen, Julia ^c   Guo, Xinhua ^a   Yazdanbakhsh, Karina ^a   Mohandas, Narla ^a   Alayash, Abdu I ^b   Manci, Elizabeth A ^d   Belcher, John D ^c   Vercellotti, Gregory M ^c  

^a NEW YORK BLOOD CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

free haemoglobin; H ferritin; haem oxygenase 1; haptoglobin; sickle cell disease

Indexed keywords

FERRITIN; HAPTOGLOBIN; HEAVY CHAIN FERRITIN; HEME OXYGENASE 1; UNCLASSIFIED DRUG; APOFERRITIN; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; ANIMAL; BLOOD CELL COUNT; COMPLICATION; DISEASE MODEL; GENE EXPRESSION; GENETICS; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; ANIMALS; APOFERRITINS; BLOOD CELL COUNT; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HAPTOGLOBINS; HEME OXYGENASE-1; IRON; KIDNEY DISEASES; MALE; MICE; MICE, TRANSGENIC; TREATMENT OUTCOME;

EID: 84983000268     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14280     Document Type: Article

References (59)

1. Allison, A.C. & Rees, W.A. (1957) The binding of haemoglobin by plasma proteins (haptoglobins); its bearing on the renal threshold for haemoglobin and the aetiology of haemoglobinuria. British Medical Journal, 2, 1137–1143.
2. Atamna, H. & Ginsburg, H. (1995) Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells. Journal of Biological Chemistry, 270, 24876–24883.
3. Azarov, I., He, X., Jeffers, A., Basu, S., Ucer, B., Hantgan, R.R., Levy, A. & Kim-Shapiro, D.B. (2008) Rate of nitric oxide scavenging by hemoglobin bound to haptoglobin. Nitric Oxide, 18, 296–302.
4. Ballantyne, C.M. & Entman, M.L. (2002) Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation, 106, 766–767.
5. Bamm, V.V., Tsemakhovich, V.A., Shaklai, M. & Shaklai, N. (2004) Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry, 43, 3899–3906.
6. Beckman, J.D., Belcher, J.D., Vineyard, J.V., Chen, C., Nguyen, J., Nwaneri, M.O., O'Sullivan, M.G., Gulbahce, E., Hebbel, R.P. & Vercellotti, G.M. (2009) Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. American Journal of Physiology. Heart and Circulatory Physiology, 297, H1243–1253.
7. Belcher, J.D., Mahaseth, H., Welch, T.E., Otterbein, L.E., Hebbel, R.P. & Vercellotti, G.M. (2006) Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. The Journal of Clinical Investigation, 116, 808–816.
8. Belcher, J.D., Vineyard, J.V., Bruzzone, C.M., Chen, C., Beckman, J.D., Nguyen, J., Steer, C.J. & Vercellotti, G.M. (2010) Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. Journal of Molecular Medicine (Berlin), 88, 665–675.
9. Belcher, J.D., Young, M., Chen, C., Nguyen, J., Burhop, K., Tran, P. & Vercellotti, G.M. (2013) MP4CO, a pegylated hemoglobin saturated with carbon monoxide is a modulator of HO-1, inflammation and vaso-occlusion in transgenic sickle mice. Blood, 122, 2757–64.
10. Belcher, J.D., Chen, C., Nguyen, J., Milbauer, L., Abdulla, F., Alayash, A.I., Smith, A., Nath, K.A., Hebbel, R.P. & Vercellotti, G.M. (2014) Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 123, 377–390.
11. Bhensdadia, N.M., Hunt, K.J., Lopes-Virella, M.F., Michael Tucker, J., Mataria, M.R., Alge, J.L., Neely, B.A., Janech, M.G. & Arthur, J.M.; Veterans Affairs Diabetes Trial (VADT) study group. (2013) Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes. Kidney International, 83, 1136–1143.
12. Buehler, P.W., Abraham, B., Vallelian, F., Linnemayr, C., Pereira, C.P., Cipollo, J.F., Jia, Y., Mikolajczyk, M., Boretti, F.S., Schoedon, G., Alayash, A.I. & Schaer, D.J. (2009) Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood, 113, 2578–2586.
13. Camus, S.M., Gausseres, B., Bonnin, P., Loufrani, L., Grimaud, L., Charue, D., De Moraes, J.A., Renard, J.M., Tedgui, A., Boulanger, C.M., Tharaux, P.L. & Blanc-Brude, O.P. (2012) Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. Blood, 120, 5050–5058.
14. Chantrathammachart, P., Mackman, N., Sparkenbaugh, E., Wang, J.G., Parise, L.V., Kirchhofer, D., Key, N.S. & Pawlinski, R. (2012) Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood, 120, 636–646.
15. Chintagari, N.R., Mishra, A., Su, L., Wang, Y., Ayalew, S., Hartson, S.D. & Liu, L. (2010) Vacuolar ATPase regulates surfactant secretion in rat alveolar type II cells by modulating lamellar body calcium. PLoS ONE, 5, e9228.
16. Chintagari, N.R., Nguyen, J., Belcher, J.D., Vercellotti, G.M. & Alayash, A.I. (2015) Haptoglobin attenuates hemoglobin-induced heme oxygenase-1 in renal proximal tubule cells and kidneys of a mouse model of sickle cell disease. Blood Cells, Molecules, & Diseases, 54, 302–306.
17. Deuel, J.W., Vallelian, F., Schaer, C.A., Puglia, M., Buehler, P.W. & Schaer, D.J. (2015) Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity. Free Radical Biology and Medicine, 89, 931–943.
18. Etzerodt, A. & Moestrup, S.K. (2013) CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxidants & Redox Signaling, 18, 2352–2363.
19. Etzerodt, A., Kjolby, M., Nielsen, M.J., Maniecki, M.B., Svendsen, P. & Moestrup, S.K. (2012) Plasma clearance of hemoglobin and haptoglobin in mice and effect of CD163 gene targeting disruption. Antioxidants & Redox Signaling, 18, 2254–63.
20. Fabry, M.E., Sengupta, A., Suzuka, S.M., Costantini, F., Rubin, E.M., Hofrichter, J., Christoph, G., Manci, E., Culberson, D., Factor, S.M. & Nagel, R.L. (1995) A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood, 86, 2419–2428.
21. Gurley, S.B., Clare, S.E., Snow, K.P., Hu, A., Meyer, T.W. & Coffman, T.M. (2006) Impact of genetic background on nephropathy in diabetic mice. American Journal of Physiology. Renal Physiology, 290, F214–222.
22. Hanson, M.S., Xu, H., Flewelen, T.C., Holzhauer, S.L., Retherford, D., Jones, D.W., Frei, A.C., Pritchard, K.A. Jr, Hillery, C.A., Hogg, N. & Wandersee, N.J. (2013) A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia. American Journal of Physiology. Heart and Circulatory Physiology, 304, H328–336.
23. Huy, N.T., Xuan Trang, D.T., Uyen, D.T., Sasai, M., Harada, S. & Kamei, K. (2005) An improved colorimetric method for quantitation of heme using tetramethylbenzidine as substrate. Analytical Biochemistry, 344, 289–291.
24. Hwang, P.K. & Greer, J. (1980) Interaction between hemoglobin subunits in the hemoglobin. haptoglobin complex. Journal of Biological Chemistry, 255, 3038–3041.
25. Irwin, D.C., Baek, J.H., Hassell, K., Nuss, R., Eigenberger, P., Lisk, C., Loomis, Z., Maltzahn, J., Stenmark, K.R., Nozik-Grayck, E. & Buehler, P.W. (2015) Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration. Free Radical Biology and Medicine, 82, 50–62.
26. Kato, G.J., Martyr, S., Blackwelder, W.C., Nichols, J.S., Coles, W.A., Hunter, L.A., Brennan, M.L., Hazen, S.L. & Gladwin, M.T. (2005) Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology, 130, 943–953.
27. Keleku-Lukwete, N., Suzuki, M., Otsuki, A., Tsuchida, K., Katayama, S., Hayashi, M., Naganuma, E., Moriguchi, T., Tanabe, O., Engel, J.D., Imaizumi, M. & Yamamoto, M. (2015) Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proceedings of the National Academy of Sciences of the United States of America, 112, 12169–12174.
28. Kristiansen, M., Graversen, J.H., Jacobsen, C., Sonne, O., Hoffman, H.J., Law, S.K. & Moestrup, S.K. (2001) Identification of the haemoglobin scavenger receptor. Nature, 409, 198–201.
29. Lim, S.K., Kim, H., Lim, S.K., bin Ali, A., Lim, Y.K., Wang, Y., Chong, S.M., Costantini, F. & Baumman, H. (1998) Increased susceptibility in Hp knockout mice during acute hemolysis. Blood, 92, 1870–1877.
30. Lim, Y.K., Jenner, A., Ali, A.B., Wang, Y., Hsu, S.I., Chong, S.M., Baumman, H., Halliwell, B. & Lim, S.K. (2000) Haptoglobin reduces renal oxidative DNA and tissue damage during phenylhydrazine-induced hemolysis. Kidney International, 58, 1033–1044.
31. Lipiski, M., Deuel, J.W., Baek, J.H., Engelsberger, W.R., Buehler, P.W. & Schaer, D.J. (2013) Human hp1-1 and hp2-2 phenotype-specific haptoglobin therapeutics are both effective in vitro and in Guinea pigs to attenuate hemoglobin toxicity. Antioxidants & Redox Signaling, 19, 1619–1633.
32. Manci, E.A., Hillery, C.A., Bodian, C.A., Zhang, Z.G., Lutty, G.A. & Coller, B.S. (2006) Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood, 107, 1651–1658.
33. Miller, S.T., Wang, W.C., Iyer, R., Rana, S., Lane, P., Ware, R.E., Li, D., Rees, R.C. & Investigators, B.-H. (2010) Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood & Cancer, 54, 265–268.
34. Mohandas, N., Clark, M.R., Jacobs, M.S. & Shohet, S.B. (1980) Analysis of factors regulating erythrocyte deformability. The Journal of Clinical Investigation, 66, 563–573.
35. Mollan, T.L., Jia, Y., Banerjee, S., Wu, G., Kreulen, R.T., Tsai, A.L., Olson, J.S., Crumbliss, A.L. & Alayash, A.I. (2014) Redox properties of human hemoglobin in complex with fractionated dimeric and polymeric human haptoglobin. Free Radical Biology and Medicine, 69, 265–77.
36. Muller-Eberhard, U., Javid, J., Liem, H.H., Hanstein, A. & Hanna, M. (1968) Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood, 32, 811–815.
37. Nielsen, M.J., Moller, H.J. & Moestrup, S.K. (2010) Hemoglobin and heme scavenger receptors. Antioxidants & Redox Signaling, 12, 261–273.
38. Polat, S.B., Ugurlu, N., Aslan, N., Cuhaci, N., Ersoy, R. & Cakir, B. (2016) Evaluation of biochemical and clinical markers of endothelial dysfunction and their correlation with urinary albumin excretion in patients with type 1 diabetes mellitus. Archives of Endocrinology and Metabolism, 60, 117–124.
39. Quimby, K.R., Hambleton, I.R. & Landis, R.C. (2015) Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease. Medical Hypotheses, 85, 424–32.
40. Rifkind, J.M., Mohanty, J.G. & Nagababu, E. (2014) The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions. Frontiers in Physiology, 5, 500.
41. Saraf, S.L., Zhang, X., Kanias, T., Lash, J.P., Molokie, R.E., Oza, B., Lai, C., Rowe, J.H., Gowhari, M., Hassan, J., Desimone, J., Machado, R.F., Gladwin, M.T., Little, J.A. & Gordeuk, V.R. (2014) Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. British Journal of Haematology, 164, 729–739.
42. Saraf, S.L., Zhang, X., Shah, B., Kanias, T., Gudehithlu, K.P., Kittles, R., Machado, R.F., Arruda, J.A., Gladwin, M.T., Singh, A.K. & Gordeuk, V.R. (2015) Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica, 100, 1275–1284.
43. Sasongko, T.H., Nagalla, S. & Ballas, S.K. (2015) Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database Systematic Review, 6, CD009191.
44. Schaer, D.J., Schaer, C.A., Buehler, P.W., Boykins, R.A., Schoedon, G., Alayash, A.I. & Schaffner, A. (2006) CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood, 107, 373–380.
45. Schaer, D.J., Buehler, P.W., Alayash, A.I., Belcher, J.D. & Vercellotti, G.M. (2013) Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood, 121, 1276–1284.
46. Schaer, D.J., Vinchi, F., Ingoglia, G., Tolosano, E. & Buehler, P.W. (2014) Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Frontiers in Physiology, 5, 415.
47. Schaer, C.A., Deuel, J.W., Schildknecht, D., Mahmoudi, L., Garcia-Rubio, I., Owczarek, C., Schauer, S., Kissner, R., Banerjee, U., Palmer, A.F., Spahn, D.R., Irwin, D.C., Vallelian, F., Buehler, P.W. & Schaer, D.J. (2015) Haptoglobin preserves vascular nitric oxide signaling during hemolysis. American Journal of Respiratory and Critical Care Medicine, 193, 1111–22.
48. Siciliano, A., Malpeli, G., Platt, O.S., Lebouef, C., Janin, A., Scarpa, A., Olivieri, O., Amato, E., Corrocher, R., Beuzard, Y. & De Franceschi, L. (2011) Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. Haematologica, 96, 24–32.
49. Smith, A. & McCulloh, R.J. (2015) Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. Frontiers in Physiology, 6, 187.
50. Smith, A. & Morgan, W.T. (1979) Haem transport to the liver by haemopexin. Receptor-mediated uptake with recycling of the protein. The Biochemical Journal, 182, 47–54.
51. Sparkenbaugh, E.M., Chantrathammachart, P., Wang, S., Jonas, W., Kirchhofer, D., Gailani, D., Gruber, A., Kasthuri, R., Key, N.S., Mackman, N. & Pawlinski, R. (2015) Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica, 100, 308–314.
52. Thomsen, J.H., Etzerodt, A., Svendsen, P. & Moestrup, S.K. (2013) The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxidative Medicine and Cellular Longevity, 2013, 523652.
53. Uzunova, V.V., Pan, W., Galkin, O. & Vekilov, P.G. (2010) Free heme and the polymerization of sickle cell hemoglobin. Biophysical Journal, 99, 1976–1985.
54. Vercellotti, G.M., Khan, F.B., Nguyen, J., Chen, C., Bruzzone, C.M., Bechtel, H., Brown, G., Nath, K.A., Steer, C.J., Hebbel, R.P. & Belcher, J.D. (2014) H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Frontiers in Pharmacology, 5, 79.
55. Vinchi, F., De Franceschi, L., Ghigo, A., Townes, T., Cimino, J., Silengo, L., Hirsch, E., Altruda, F. & Tolosano, E. (2013) Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation, 127, 1317–29.
56. Vinchi, F., Costa da Silva, M., Ingoglia, G., Petrillo, S., Brinkman, N., Zuercher, A., Cerwenka, A., Tolosano, E. & Muckenthaler, M.U. (2016) Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood, 127, 473–486.
57. Wu, L.C., Sun, C.W., Ryan, T.M., Pawlik, K.M., Ren, J. & Townes, T.M. (2006) Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood, 108, 1183–1188.
58. Yang, F., Haile, D.J., Berger, F.G., Herbert, D.C., Van Beveren, E. & Ghio, A.J. (2003) Haptoglobin reduces lung injury associated with exposure to blood. American Journal of Physiology. Lung Cellular and Molecular Physiology, 284, L402–409.
59. Zhou, Z., Behymer, M. & Guchhait, P. (2011) Role of extracellular hemoglobin in thrombosis and vascular occlusion in patients with sickle cell anemia. Anemia, 2011, 918916.